GRI logo

GRI Bio, Inc. Common Stock

GRI

GRI: GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis.

more

Show GRI Financials

All
Government
Consumer Interest
SEC Filings
ESG/Other

Recent trades of GRI by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard

Recently reported changes by institutional investors

Quarterly net insider trading by GRI's directors and management

Quiver Logo

No recent Insider Trading for this ticker

Insider Trading Dashboard

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Prevention and treatment of inflammatory conditions May. 30, 2023
  • Patent Title: Hydroxy-substituted amino and ammonium derivatives and their medical use Jan. 31, 2023
  • Patent Title: Oxygenated amino- or ammonium-containing sulfonic acid, phosphonic acid and carboxylic acid derivatives and their medical use Sep. 27, 2022
  • Patent Title: Hydroxy-substituted amino and ammonium derivatives and their medical use Mar. 23, 2021
  • Patent Title: Prevention and treatment of inflammatory conditions Feb. 23, 2021
  • Patent Title: Amino- or ammonium-containing sulfonic acid, phosphonic acid and carboxylic acid derivatives and their medical use Nov. 10, 2020
  • Patent Title: Oxygenated amino- or ammonium-containing sulfonic acid, phosphonic acid and carboxylic acid derivatives and their medical use Oct. 27, 2020
  • Patent Title: Hydroxy-substituted amino and ammonium derivatives and their medical use Dec. 04, 2018
  • Patent Title: Prevention and treatment of inflammatory conditions Apr. 24, 2018
  • Patent Title: Amino- or ammonium-containing sulfonic acid, phosphonic acid and carboxylic acid derivatives and their medical use Dec. 26, 2017
  • Patent Title: Oxygenated amino- or ammonium-containing sulfonic acid, phosphonic acid and carboxylic acid derivatives and their medical use Sep. 05, 2017
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
WallStreetBets

Number of mentions of GRI in WallStreetBets Daily Discussion

GRI News

Recent insights relating to GRI

CNBC Recommendations

Recent picks made for GRI stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in GRI

Corporate Flights

Flights by private jets registered to GRI